Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles

被引：3
|
作者：
Helleday, T. [1 ,2 ]
机构：
[1] Univ Sheffield, Dept Oncol & Metab, Weston Pk Canc Ctr, Sheffield, S Yorkshire, England
[2] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷 / 02期
基金：
瑞典研究理事会;
关键词：
PD-1; BLOCKADE;
D O I：
10.1016/j.annonc.2019.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [41] Evaluation of efficacy and immune response to PD1 checkpoint inhibition in human immune-reconstituted mice using patient-derived xenograft models
    Izadi, Hooman
    Broudy, Tommy
    Yan, Deborah
    Thatte, Jayant
    CANCER RESEARCH, 2017, 77
  • [42] Potential for Cell-Mediated Immune Responses in Mouse Models of Pelizaeus-Merzbacher Disease
    Southwood, Cherie M.
    Fykkolodziej, Bozena
    Dachet, Fabien
    Gow, Alexander
    BRAIN SCIENCES, 2013, 3 (04) : 1417 - 1444
  • [43] PRECLINICAL STUDY USING A GLUTAMATERGIC SIGNALING AND IMMUNE-CHECKPOINT INHIBITORS IN A SPONTANEOUS MELANOMA PRONE MOUSE MODEL
    Eddy, Kevinn
    Marinaro, Christina
    Rasheed, Maryam
    Campagnolo, Joseph
    Zhong, Xiaoxuan
    Eddin, Mohamad
    Shah, Raj
    Gupta, Kajal
    Diaz, Jesus
    Zloza, Andrew
    Chen, Suzie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A467 - A467
  • [44] Establishment of Human Leukocyte Antigen-Mismatched Immune Responses after Transplantation of Human Liver Bud in Humanized Mouse Models
    Mori, Akihiro
    Murata, Soichiro
    Tashiro, Nao
    Tadokoro, Tomomi
    Okamoto, Satoshi
    Otsuka, Ryo
    Wada, Haruka
    Murata, Tomoki
    Takahashi, Takeshi
    Seino, Ken-ichiro
    Taniguchi, Hideki
    CELLS, 2021, 10 (02) : 1 - 14
  • [45] Enhancing the therapeutic efficacy of immune checkpoint inhibition and targeted therapy using anti-tumor antibodies in mouse melanoma
    Perez-Lorenzo, R.
    Erjavec, S.
    Clynes, R.
    Christiano, A. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S205 - S205
  • [46] Understanding Clinical Responses to Immune Checkpoint Therapies Using a Novel Neoantigen-Rich Murine Melanoma Cell Model
    Stancu, Andreea
    Prestegarden, Lars
    Widlund, Hans
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 499 - 500
  • [47] Understanding Clinical Responses to Immune Checkpoint Therapies Using a Novel Neoantigen-Rich Murine Melanoma Cell Model
    Stancu, Andreea
    Prestegarden, Lars
    Widlund, Hans
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 499 - 500
  • [48] Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
    Lee, Jeongshim
    Chang, Jee Suk
    Roh, Mi Ryung
    Jung, Minkyu
    Lee, Choong-Kun
    Oh, Byung Ho
    Chung, Kee Yang
    Koom, Woong Sub
    Shin, Sang Joon
    CANCER RESEARCH AND TREATMENT, 2020, 52 (03): : 730 - 738
  • [49] Immune profiling uncovers neo-antigens and TCR repertoire responding to WX-mPD-1 and WX-mPD-L1 immune checkpoint inhibitors in syngeneic mouse xenograft models
    Dong, Hua
    Lu, Yan
    Zhang, Qiyao
    Zhang, Lingling
    Chen, Xiaoyue
    Yang, Guizhu
    Yang, Shuqun
    He, Miao
    Tang, Xuzhen
    Qin, Yuxin
    Zheng, Yong
    Cai, Jiexing
    Cang, Yong
    Yan, Shaoyu
    Li, Jing
    Ji, Qunsheng
    CANCER RESEARCH, 2016, 76
  • [50] Antigen-specific immune responses in melanoma using stereotactic radiotherapy combined with anti-PD1 checkpoint blockade
    Sharabi, Andrew
    Nirschl, Christopher
    Ceccato, Tina
    Francica, Brian
    Alme, Angela
    Nirschl, Thomas
    Velarde, Esteban
    DeWeese, Theodore
    Drake, Charles
    CANCER RESEARCH, 2014, 74 (19)
12345